We performed a prospective , randomized , double-blind , placebo-controlled trial of adults with eosinophilic esophagitis given an antibody against IgE ( omalizumab , n = 16 ) or placebo ( n = 14 ) every 2-4 weeks for 16 weeks , based on weight and serum level of IgE .